Condition: End Stage Renal Disease (ESRD) · Maintenance Hemodialysis · Sponsor: Yunfeng Xia
Many maintenance hemodialysis (MHD) patients develop negative outlooks due to their illnesses and complications, making their quality of life and prognosis a clinical concern. Effective life management and treatment cooperation are crucial to improving dialysis quality and patient outcomes. This trial aims to evaluate whether management through the "Yueya" mini-program and WeChat can provide personalized guidance such as health education, diet, exercise, medication supervision, and condition monitoring to enhance treatment compliance, quality of life, strengthen quality control in the hemodialysis unit, and improve patient prognosis. Patients will be divided into a group receiving support via the "Yueya" mini-program and WeChat, and a control group receiving routine care. Clinical and laboratory indicators, cardiovascular events, death, hospitalization, quality of life, and compliance will be recorded and compared between groups to assess the impact of APP-assisted patient management on the quality of MHD blood purification therapy and the prognosis of MHD patients.
This description comes directly from the study's public registry record.
Yunfeng Xia Dr · 86-023-89012687 · yunfengxia0920@126.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Chongqing Medical University | Chongqing, Chongqing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07291154